Cardioprotective actions of adenosine and adenosine analogs.
Cook
M A
MA
Department of Pharmacology and Toxicology, University of Western Ontario, London, Canada.
Karmazyn
M
M
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000502:physiology; D058892:Adenosine Deaminase Inhibitors; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001693:Biological Transport, Active; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000187:drug effects*; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D019157:Ischemic Preconditioning, Myocardial; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D009705:Nucleosides / Q000378:metabolism; D015221:Potassium Channels / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000145:classification / Q000187:drug effects / Q000502:physiology
D058892:Adenosine Deaminase Inhibitors; D009705:Nucleosides; D015221:Potassium Channels; D018047:Receptors, Purinergic P1; D000255:Adenosine Triphosphate; D011493:Protein Kinase C; D000241:Adenosine